.

Deeper Knowledge, Faster

  • Anticipate your formulary budget
  • Identify first generic entrants
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Argus Health
Federal Trade Commission
Express Scripts
Julphar
Boehringer Ingelheim
Chinese Patent Office
Novartis
Baxter
Accenture

Generated: June 24, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 012380

« Back to Dashboard
NDA 012380 describes ZARONTIN, which is a drug marketed by Parke-davis and Parke Davis and is included in two NDAs. It is available from two suppliers. Additional details are available on the ZARONTIN profile page.

The generic ingredient in ZARONTIN is ethosuximide. There is one drug master file entry for this compound. Twelve suppliers are listed for this compound. Additional details are available on the ethosuximide profile page.

Summary for NDA: 012380

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Anticonvulsants
Formulation / Manufacturing:see details

Pharmacology for NDA: 012380

Suppliers and Packaging for NDA: 012380

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ZARONTIN
ethosuximide
CAPSULE;ORAL 012380 NDA Parke-Davis Div of Pfizer Inc 0071-0237 0071-0237-24 100 CAPSULE in 1 BOTTLE (0071-0237-24)
ZARONTIN
ethosuximide
CAPSULE;ORAL 012380 NDA AUTHORIZED GENERIC Greenstone LLC 59762-2250 59762-2250-2 100 CAPSULE in 1 BOTTLE (59762-2250-2)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength250MG
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Harvard Business School
UBS
McKesson
Citi
Fish and Richardson
Covington
Federal Trade Commission
Colorcon
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot